# Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept

> **NCT01379508** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 241 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** telbivudine
- **DRUG:** tenofovir disoproxil fumarate

## Key facts

- **NCT ID:** NCT01379508
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-21
- **Primary completion:** 2015-12-10
- **Final completion:** 2015-12-10
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2018-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01379508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01379508, "Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01379508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*